Dr. Reddy's Laboratories announces the launch of ColchicineTablets USP, 0.6 mg in the U.S. Market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Colchicine Tablets USP, a therapeutic equivalent generic version of Colcrys® (colchicine) Tablets, 0.6 mg, approved by the U.S. Food and Drug Administration (USFDA).

The Colcrys® brand and generic market had U.S. sales of approximately $491 million MAT for the most recent twelve months ending in March 2020 according to IQVIA Health*.

Dr. Reddy's Colchicine is available in 0.6 mg tablets in bottle count sizes of 30s and 100s.

Colcrys® is a trademark of Takeda

Shares of DR.REDDY's LABORATORIES LTD. was last trading in BSE at Rs.4065.95 as compared to the previous close of Rs. 4114.85. The total number of shares traded during the day was 24224 in over 2937 trades.

The stock hit an intraday high of Rs. 4126.85 and intraday low of 4036.8. The net turnover during the day was Rs. 99136532.

Source : Equity Bulls

Keywords